The law, slated to take effect in September, requires health plans to cover the treatment given by in-network providers, not ...

NEW YORK – The US Food and Drug Administration on Wednesday granted accelerated approval to Dizal's oral EGFR inhibitor Zegfrovy (sunvozertinib) as a treatment for patients with locally advanced or ...

The company is betting that the alternative cytotoxic payload in its ADC can overcome resistance in patients who relapse on Enhertu.

The study will use a companion lipid biomarker test to identify those with a poor prognosis who are potential best responders.